Objectives: Effective treatment of Gram-negative bacterial infections is increasingly challenging due to the spread of multidrug-resistant strains and a lack of new antimicrobials in development. Bacterial type I signal peptidases (SPases) represent a highly conserved and essential target for inhibition by novel compounds. SPases are required for the effective processing of membrane translocated proteins involved in core functions related to metabolism, virulence and resistance. In this study we assessed the biochemical and functional activity of a novel synthetic inhibitor (MD3) of SPases against a wide range of Gram-negative pathogens.
Introduction
There is an urgent need for new agents for the treatment of Gram-negative infections due to the global spread of multidrugresistant (MDR) strains and a dearth of novel synthetic compounds beyond the early phases of development. The most pressing needs are for drugs able to target the 'ESKAPE' group of pathogens, which include MDR strains of Pseudomonas aeruginosa, Acinetobacter baumannii and carbapenem-resistant Enterobacteriaceae. 1 The development of compounds that target core metabolic processes conserved amongst a wide range of MDR bacteria needs to be accelerated and one target that has not been exploited in these organisms is the type I signal peptidase (SPase). SPases are cytoplasmic membrane-bound enzymes, critical to the effective processing of immature proteins in bacteria by cleaving the aminoterminal signal peptides of proteins translocated by the general secretion (Sec) pathway.
Type I signal peptides have three conserved domains: a positively charged amino-terminus, a central hydrophobic region and a hydrophilic carboxy-terminal domain containing the SPase cleavage site. 2 In P. aeruginosa there are predicted to be more than 800 proteins (.14% of the proteome) that possess type I signal peptides, including proteins involved in iron uptake, flagellar biosynthesis, virulence (elastases LasA and LasB) antimicrobial resistance (AmpC b-lactamase), global regulation and many Sec-independent twin-arginine translocation (TAT) pathway substrates. 3 -6 This suggests a direct role for SPases in cellular housekeeping and pathogenesis, and this was confirmed in our recent study that demonstrated LepB to be the primary SPase of P. aeruginosa and essential for viability, whilst its paralogue PA1303 was found to be dispensable yet still involved in virulence factor secretion. 7 Importantly, LepB is highly conserved amongst P. aeruginosa clinical isolates, is not a target of existing therapies and is thus an attractive target for a new inhibitor. The suitability of SPases as drug targets more widely is supported by literature showing them to be ubiquitous amongst bacteria and essential in all bacterial species examined so far. 7 -10 SPase enzymes operate via a unique Ser/Lys catalytic dyad enabling specific inhibition and the active site is located on the outer surface of the cytoplasmic membrane, making it accessible to any inhibitor able to traverse the outer membrane (OM) of Gram-negative organisms. 11 Furthermore, monomeric bacterial SPases are structurally different from the multimeric SPases of eukaryotes, which gives confidence that selective toxicity using novel inhibitors can be achieved. 2 SPases are not sensitive to classical inhibitors of serine, cysteine, aspartic and metalloproteases. 12 However, b-lactam analogues, as well as arylomycin and lipoglycopeptide natural products, have been shown to inhibit SPase activity. 13 -17 Unfortunately, only modest antibacterial activity has so far been demonstrated for these inhibitors, mostly against Gram-positive bacteria organisms, and no studies to date have reported antibacterial activity against P. aeruginosa strains that have not been genetically sensitized. 15, 17, 18 A synthetic b-aminoketone inhibitor, MD3 [1-(2,5-dichlorophenyl)-3-(dimethylamino)propan-1-one] was identified during a screening of a library of compounds for their ability to inhibit recombinant Escherichia coli SPase (LepB). 19 It has antimicrobial activity against Staphylococcus aureus, Haemophilus influenzae, Moraxella catarrhalis and Mycobacterium tuberculosis, and E. coli can be sensitized in the presence of the OM-permeabilizing agent-polymyxin B nonapeptide (PMBN). 19, 20 However, the activity of MD3 has not been fully assessed against MDR Gram-negative pathogens. Following our previous molecular characterization of SPases in P. aeruginosa, 7 the aim of this study was to use MD3 as a known SPase inhibitor to determine whether targeting SPase function in this organism and other Gram-negative pathogens (A. baumannii, Klebsiella pneumoniae and Stenotrophomonas maltophilia) is a valid antimicrobial strategy that could be exploited in future antibiotic development programmes. Given the previous requirement of PMBN to render E. coli susceptible to MD3, the location of SPases on the outer surface of the cytoplasmic membrane and the known formidable barrier of the OMs of the Gram-negative pathogens studied, we also assessed the antimicrobial activity of MD3 in the presence of OM-permeabilizing agents in order to establish the potential use of SPase inhibitors as part of a combination therapy.
Materials and methods

Bacterial isolates, culture media and chemicals
The isolates used in this study along with their characteristics and reasons for inclusion are listed in Table 1 . Strains were routinely grown in Iso-Sensitest medium (Oxoid Ltd, Basingstoke, UK) at 378C. For the maintenance of genetically modified strains, media were supplemented with gentamicin (200 mg/L) and/or tetracycline (100 mg/L for P. aeruginosa and 15 mg/L for E. coli) where required. Resistance determinants and epidemiological markers amongst clinical isolates studied were determined by PCR and sequencing methods as previously described (Table 1) . 21, 22 The SPase inhibitor MD3 was synthesized as previously described and provided by Professor Tanya Parish (IDRI, Seattle, WA, USA).
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MD3 target validation assay
The specificity of MD3 as an inhibitor of type I signal peptidases was determined using recombinant P. aeruginosa LepB and fluorescence resonance energy transfer (FRET) technology using a previously described assay. 7 Two intramolecularly quenched fluorescent substrates were evaluated; LasB FRET (Dabcyl-VSPAAFAADL-EDANS, purchased from Peptide Protein Research Ltd, UK) contains a decapeptide based on the cleavage region of the signal peptide sequence of the P. aeruginosa LasB protein, while SceD FRET (Dabcyl-AGHDAHASET-EDANS, purchased from AnaSpec) spans the signal peptide cleavage site of the Staphylococcus epidermidis SceD protein. For IC 50 value determination, MD3 was tested in triplicate at concentrations ranging from 3 to 38 mM with LasB FRET and from 6 to 100 mM using SceD FRET. IC 50 values were calculated using GraphPad Prism software and the sigmoidal dose -response function. DMSO (Sigma Aldrich) at 0.5% (v/v) was used as a negative control.
Construction of a lepB-regulatable strain (DlepB/pHERD26T-lepB)
In order to place lepB under the control of an arabinose-inducible promoter (P BAD ), this gene was amplified from P. aeruginosa PAO1 and cloned into the shuttle vector pHERD26T to generate plasmid pHERD26T-lepB. 23 The primers involved in the construction and sequencing of this plasmid are listed in Table S1 (available as Supplementary data at JAC Online). A strain containing a chromosomal lepB deletion and harbouring lepB in trans on pHERD26T-lepB (DlepB/pHERD26T-lepB) was generated and confirmed as previously described. 7 The effect of MD3 on the growth of the lepB regulatable strain (DlepB/ pHERD26T-lepB) was determined by measuring OD at 595 nm (BioTek ELx800 plate reader) after overnight growth at 378C in Iso-Sensitest broth containing several different concentrations of L-arabinose (0.025%, 0.05%, 0.075% and 0.1%).
In vitro activity of MD3 versus Gram-negative pathogens
The activity of MD3 was assessed against susceptible type strains and MDR clinical isolates of P. aeruginosa, K. pneumoniae, S. maltophilia and A. baumannii (see Table 2 ). MICs were determined by broth microtitre dilution using Iso-Sensitest broth in 96-well plates and a bacterial inoculum of 10 4 cfu/mL. Following incubation at 378C in air for 24 h, the lowest concentration of MD3 that inhibited visual growth of bacteria (no turbidity) was recorded as the MIC. If an MIC could not be determined visually at the highest concentration of MD3 used (28 mg/L), viable counts were performed to assess the percentage survival of bacteria and establish whether MD3 had any intrinsic activity alone.
The MIC of MD3 was also determined in the presence of OM-permeabilizing agents (Sigma-Aldrich) added at the following concentrations: sodium hexametaphosphate (NaHMP), 4 mg/mL; and PMBN, 10 mg/L (E. coli) and 1 or 5 mg/L (P. aeruginosa). Colistin sulphate (Sigma Aldrich) was also used at the subinhibitory concentrations listed in Table 2 to assess synergy with a membrane-disrupting agent with intrinsic antimicrobial activity.
Statistical analysis
Data were analysed using the Student's t-test (two independent samples assuming unequal variances). Differences were statistically significant at P, 0.05. The degree of spread of the data is shown as standard deviation.
Signal peptidase inhibition in Gram-negative bacteria 3237 
JAC
Results
Inhibition of the P. aeruginosa SPase LepB by MD3
The ability of MD3 to inhibit the enzymatic activity of recombinant P. aeruginosa SPase LepB was determined using FRET technology. In this assay, the internally quenched fluorescent peptide substrate sequence was based on the signal peptide sequence cleavage region of P. aeruginosa preproenzyme elastase LasB, a well-characterized secreted virulence factor. A characteristic of type I signal peptides is that alanine residues are the most common amino acids at positions 21 and 23 relative to the cleavage site and the LasB signal peptide cleavage site has been experimentally identified as the peptide bond between the alanine residues at positions 23 and 24 relative to the N-terminal methionine. 5 The peptide substrate Dabcyl-VSPAAFAADL-EDANS was designed to span 10 amino acids of the LasB signal peptide cleavage region (alanine residues 7 and 8 corresponding to positions 23 and 24 of the preproenzyme) and we have previously demonstrated dosedependent cleavage of this peptide by recombinant P. aeruginosa LepB enzyme. 7 When MD3 was incorporated into the assay, cleavage of this LasB FRET peptide by LepB (1 mM) was found to be inhibited and an IC 50 of 8 mM (R 2 ¼ 0.99) was observed ( Figure 1a ). Inhibition of LepB activity by MD3 was confirmed using a second Personne et al. Signal peptidase inhibition in Gram-negative bacteria 3239 JAC peptide (Dabcyl-AGHDAHASET-EDANS) based on the signal peptide sequence of the pre-SceD protein from S. epidermidis (cleavage site, A-S bond), also containing alanine residues at positions 21 and 23 relative to the SPase cleavage site and validated as a means for assessing the in vitro activity of SPases of S. epidermidis and S. aureus. 16, 24 This alternative peptide sequence was also cleaved by recombinant LepB protein and MD3 inhibited this reaction with an IC 50 value of 11.9 mM (R 2 ¼0.97) (Figure 1b ). These data using two different SPase cleavage sequences provide convincing evidence that MD3 is an effective inhibitor of the enzymatic activity of the P. aeruginosa LepB SPase.
Susceptibility of P. aeruginosa to MD3 is dependent on lepB expression
The antimicrobial activity of MD3 was confirmed by testing it against E. coli. This organism is known to be sensitized to MD3 in the presence of 10 mg/L PMBN, 19 and in our analysis an MIC of 12.5 mM (3.5 mg/L) for E. coli ATCC 25922 was observed.
MD3 alone was found not to be active against P. aeruginosa PAO1 and ATCC 27853 with no inhibition of growth observed when challenged with MD3 at 28 mg/L (100 mM) ( Table 2) . As under-expression of a drug target is a known strategy for sensitizing bacteria and confirming on-target activity of experimental agents, we constructed a lepB-regulatable derivative in strain PAO1 (DlepB/pHERD26T-lepB). In this strain the lepB gene was removed (amino acids 18-252 are deleted from the chromosome and replaced by a gentamicin resistance cassette) and was complemented with a functional copy of lepB under the control of an arabinose-inducible promoter provided in trans (pHERD26T-lepB). Growth of this strain was found to be directly correlated with levels of LepB expression, with dose-dependent decreases in growth observed upon reducing the concentration of L-arabinose to 0.05% and 0.025% (Figure 2) . No growth was observed in the absence of arabinose, confirming lepB as an essential gene in P. aeruginosa growth (Figure 2) , or in the presence of 1% L-arabinose (data not shown), suggesting that lepB expression is tightly regulated and that overexpression may be toxic to the cell.
MD3 at 28 mg/L was able to significantly reduce the growth of the lepB-regulatable strain across all concentrations of L-arabinose supplementation (P, 0.001), but was most marked in the 0.025% -0.075% range (2-to 8-fold reduction compared with the paired control culture) (Figure 2 ). These data also highlight that, in the presence of MD3, growth can be returned to almost control levels at the highest level of lepB expression examined (0.1% L-arabinose, only a 1.06-fold reduction compared with the paired control culture) (Figure 2 ).
MD3 has antibacterial activity against P. aeruginosa in the presence of OM permeabilizers
Translocation of compounds across the OM is a significant barrier to the potency of many antibiotics against P. aeruginosa. 25 We assessed synergy between MD3 and a number of agents known to increase the permeability of the OM. PMBN inhibits the growth of P. aeruginosa at much lower concentrations than are seen with E. coli 26 and did not facilitate antibacterial activity for MD3 against P. aeruginosa at the concentrations of PMBN used (1 and 5 mg/L, MIC 10 mg/L). However NaHMP, a chelating agent and effective OM permeabilizer of P. aeruginosa, 27 at 4 mg/mL inhibited the growth of ATCC 27853 and PAO1 in the presence of 28 mg/L MD3. Viable counts after overnight exposure to MD3 showed a ≥10-fold reduction in cfu/mL when compared with untreated controls ( Table 2 ). The MIC of the MD3/NaHMP combination ranged from 14 to 28 mg/L (sensitization factor ≥2 to ≥4) for three MDR cystic fibrosis isolates (CF1092, CF2004 and CF2828) ( Table 2 ). Synergy was also observed when MD3 was combined with colistin, a drug with both intrinsic antimicrobial and cellpermeabilizing properties. 28 -31 Interestingly, after exposure to sub-MIC concentrations of colistin (0.5 -0.75 mg/L) paradoxical effects on the susceptibility of MDR and susceptible P. aeruginosa isolates were observed with MICs ranging from 3.5 to 14 mg/L (CF2004, CF1092 and PA11; sensitization factors ≥4 to ≥16-fold), whilst little activity was observed against ATCC 27853 and PAO1 (MICs ≥28 mg/L) ( Table 2) .
Antimicrobial activity of MD3 against other Gram-negative bacteria
The activity of MD3 alone and in combination with NaHMP or colistin was tested against selected strains of three other Gram-negative pathogens-A. baumannii, K. pneumoniae and S. maltophilia. A BLASTP search of A. baumannii, K. pneumoniae and S. maltophilia genome sequences revealed the presence of putative SPases in all three organisms. Both A. baumannii and K. pneumoniae possess a single SPase homologue (sequence identities with P. aeruginosa PAO1 LepB, 41% and 40%, respectively), whilst S. maltophilia K279a harbours two SPase homologues (sequence identities to PAO1 LepB, 41% and 32%). All of these proteins contain the characteristic catalytic Ser/Lys dyad, and the four regions of significant sequence homology that make up the conserved catalytic domain (referred to as boxes B to E) associated with these enzymes, suggesting that MD3 may also be capable of inhibiting these enzymes (Figure 3 ). Personne et al.
When tested alone MD3 was found to have activity against A. baumannii ATCC 19606 with an 88% reduction in the viable count observed after exposure to 28 mg/L MD3. In combination with OM permeabilizers, MICs as low as 3.5 mg/L (sensitization factor of ≥16) and 0.5 mg/L (sensitization factor of ≥112) were seen with NaHMP (4 mg/mL) and colistin (0.25 mg/L), respectively ( Table 2) . We also observed evidence of antimicrobial activity against seven clinical MDR strains (AB14, AB16, AB186, AB205, AB211, AB219 and AB292) alone and MICs ranging from 1.75 to 14 mg/L (sensitization factors ≥4 to ≥32) in combination with NaHMP (4 mg/mL) and from 0.9 to 14 mg/L (sensitization factors of ≥4 to ≥62) with sub-MIC concentrations of colistin (0.25 -2 mg/L) ( Table 2) .
MD3 showed a similar profile of activity against S. maltophilia, with intrinsic activity observed against NCTC 10258 and against two of three MDR strains (Sm59 and Sms01). MICs in the presence of 4 mg/mL NaHMP ranged from 14 to 28 mg/L (sensitization factor range ≥2 to ≥4) and between 1.75 and 7 mg/L, (sensitization factor range ≥8 to ≥32) in combination with colistin (0.5 mg/L) ( Table 2 ).
K. pneumoniae appeared to be the least susceptible to MD3. In combination with 0.25 mg/L colistin an MIC of 3.5 mg/L was observed against NCTC 9633. No activity was seen either alone or in combination against the four clinical MDR strains tested (KP10, KP51, KPC-3 and KP7) ( Table 2) .
Discussion
As the incidence of MDR Gram-negative bacteria increases there is a critical need for novel drugs targeting different cellular pathways to currently used antibiotics. In this study we show that SPase inhibition in combination with membrane permeabilization may be a useful approach to be developed for treating infections caused by these organisms.
Using a lepB-regulatable derivative of P. aeruginosa we observed that reducing LepB concentrations results in impaired or no growth, thus confirming that LepB is the primary SPase and that expression of PA1303 alone cannot support the growth of this organism. MD3 acts as an effective inhibitor of recombinant P. aeruginosa LepB with an average IC 50 value of 10 mM against Figure 3 . Alignment of SPase amino acid sequences. LepB (SPase) amino acid sequences (http://www.ncbi.nlm.nih.gov/) from the following strains used: PAO1, P. aeruginosa PAO1; Ab, A. baumannii ATCC 19606; Kp, K. pneumoniae VA360; and Sm, S. maltophilia K279a. The sequences were aligned using CLUSTAL W 1.83 (www.ch.embnet.org). Conserved boxes A-E (shaded grey) were identified using sequence alignments and the following consensus motifs, which are read with an upper-case underlined character denoting absolutely conserved, an upper-case character denoting conserved and 'x' denoting not conserved: box B, IPSGSMxPTLx; box C, RGDIVVFxxP; box D, YIKRxxGxPGDxV; box E, VPxGxYFxMGDNRDNSxDSR. 12, 41 Box A (transmembrane region) is labelled as previously identified. 41 The catalytic serine and lysine residues are boxed. Identical residues are also indicated (asterisks), as are conserved residues (colons).
Signal peptidase inhibition in Gram-negative bacteria 3241 JAC two different peptide substrates, and this activity is comparable to that previously observed using recombinant E. coli LepB (IC 50 of 5 mM) in a different biochemical assay. 19 We also demonstrated on-target activity for MD3 using an engineered strain of P. aeruginosa in which lepB was under-expressed, and improved activity in the presence of two membrane-permeabilizing agents (NaHMP and colistin) with the greatest synergy observed when MD3 was combined with colistin against MDR strains of P. aeruginosa. Importantly, this is the first study to find antibacterial activity against the wild-type LepB enzyme of P. aeruginosa. At present the number of SPase inhibitors is small, but it includes a number of b-lactam analogues, arylomycins and lipoglycopeptide compounds. 13, 15, 17, 18 Arylomycins are natural products that show antibacterial activity; however, P. aeruginosa, like many other bacteria, are not susceptible to arylomycin due to a specific proline residue within the target SPase that disrupts interactions with the lipopeptide tail of the antibiotic. However, P. aeruginosa can be rendered susceptible through mutation of this proline residue in LepB. 15, 32 In this study we observed that, in general, MD3 together with colistin was a more potent combination than MD3 with NaHMP. In addition, the most dramatic antimicrobial activity was observed against both type and colistin-susceptible MDR strains of A. baumannii when they were challenged with MD3 in combination with colistin (MD3 MICs 0.5 -3.5 mg/L, sensitization factor range ≥16 to ≥112), although MD3 appeared to have some intrinsic activity alone. Similarly strains of S. maltophilia were also sensitized to MD3 in the presence of colistin. These data suggest that SPase inhibition in combination with colistin may be a valid strategy for targeting these pathogens. Against colistin-resistant strains of A. baumannii the activity of MD3 was enhanced with addition of NaHMP (MICs of 1.75 and 3.5 mg/L for strains AB205 and AB219), suggesting that SPase inhibition in combination with an alternative membrane-permeabilizing agent could be pursued as an alternative strategy.
Whether the potent synergy observed using MD3 and colistin is due to the OM-damaging activity of colistin, enabling MD3 to bind more readily to the inner membrane-bound SPase target or whether the relationship between the two drugs is co-operative will only be established once MD3 is tested in combination with OM permeabilizers that are more effective than NaHMP. Interestingly it has been found in E. coli that gross defects in cell architecture and membrane integrity occur upon depletion of cellular LepB protein concentrations; 33 therefore the development of more potent SPase inhibitors could also have the dual benefit of potentiating the activity of a partner drug during combination therapy of Gram-negative bacteria.
Although MD3 has been reported to be biochemically unstable, a synthesized breakdown product (MD4) was shown to retain both biochemical and antibacterial activity, and thus optimization of this chemical class should focus around this reactive analogue. 19 Nevertheless, the potent activity of MD3 in combination with colistin against MDR strains of A. baumannii and S. maltophilia and the evidence of broader activity against P. aeruginosa and K. pneumoniae emphasizes the need for new and more potent SPase inhibitors. Either structurally adjusted analogues of existing natural products or rationally designed synthetic inhibitors could form the basis for future mono or combination therapies for Gram-negative bacteria. Furthermore, as the antimicrobial therapeutic options are becoming more limited for healthcare professionals, this study highlights that the identification of effective novel drug combinations deserves further exploration and suggests that experimental compounds should not necessarily be discarded as inhibitors of Gram-negative bacteria if they are ineffective as a monotherapy.
